- Home
- HQY vs ROIV Comparison
HQY vs ROIV Comparison
Compare HQY & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HQY
- ROIV
- Stock Information
- Founded
- HQY 2002
- ROIV 2014
- Country
- HQY United States
- ROIV United Kingdom
- Employees
- HQY N/A
- ROIV N/A
- Industry
- HQY Business Services
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- HQY Consumer Discretionary
- ROIV Health Care
- Exchange
- HQY Nasdaq
- ROIV Nasdaq
- Market Cap
- HQY 7.9B
- ROIV 8.1B
- IPO Year
- HQY 2014
- ROIV N/A
- Fundamental
- Price
- HQY $88.51
- ROIV $11.94
- Analyst Decision
- HQY Strong Buy
- ROIV Buy
- Analyst Count
- HQY 13
- ROIV 3
- Target Price
- HQY $116.77
- ROIV $15.25
- AVG Volume (30 Days)
- HQY 914.3K
- ROIV 4.5M
- Earning Date
- HQY 09-02-2025
- ROIV 08-11-2025
- Dividend Yield
- HQY N/A
- ROIV N/A
- EPS Growth
- HQY 48.80
- ROIV N/A
- EPS
- HQY 1.37
- ROIV N/A
- Revenue
- HQY $1,243,021,000.00
- ROIV $23,233,000.00
- Revenue This Year
- HQY $9.69
- ROIV N/A
- Revenue Next Year
- HQY $8.89
- ROIV $281.14
- P/E Ratio
- HQY $64.49
- ROIV N/A
- Revenue Growth
- HQY 19.21
- ROIV N/A
- 52 Week Low
- HQY $73.84
- ROIV $8.73
- 52 Week High
- HQY $116.65
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- HQY 39.64
- ROIV 57.46
- Support Level
- HQY $87.27
- ROIV $11.60
- Resistance Level
- HQY $90.00
- ROIV $12.18
- Average True Range (ATR)
- HQY 2.53
- ROIV 0.30
- MACD
- HQY 0.06
- ROIV 0.01
- Stochastic Oscillator
- HQY 10.01
- ROIV 81.25
About HQY HealthEquity Inc.
HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.